aTyr Pharma, Inc. Common Stock

ATYR XNAS BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Market Cap

46M

Short interest (Jul 15)

8.4%

Net Short (Jul 27 ): -0.1%

Borrow Fee

1.59%

↑ 4.0%

Available Shares

3M

↑ 2.0%

Price Chart

Company Overview

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Company Info

Exchange: NASDAQ
Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK: 0001339970
Asset Type: CS

Market Data

Market Cap: $46,407,638
Employees: 58
Status: Active

Short Interest

Current Borrow Fee 1.59%
Range: 1.57% - 1.80%
Available Shares 3M
Range: 2.2M - 2.8M

Recent Changes

Fee Change: ↓ 31.7%
Available Change: ↑ 4.3%

Quick Actions

View Dilution Chart
Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime